
COAG
Healthcare · Biotechnology · $1.91B market cap
$40.86+1.48 (+3.8%)Nov 13, 4:26 PM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -7.7% over 90 days · 30-day revisions 0 up, 2 down
Beat estimates in 0 of the last 3 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 10, 2026 | Before the open | -0.51 | -0.58 | -13.7% |
| Aug 11, 2026 | Before the open | -0.63 | -0.80 | -27.0% |
| Jun 3, 2026 | Time not confirmed | — | -0.49 | — |
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2…